NCT06203600 2026-03-17
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
National Cancer Institute (NCI)
Phase 2/3 Recruiting
National Cancer Institute (NCI)
Bristol-Myers Squibb
Pfizer
Seagen Inc.
CancerCare Manitoba
UNICANCER
Wales Cancer Trials Unit